A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke

International Journal of Stroke

Volumn 8, Issue 2, 2013, Pages 95-104

  Lang, Wilfried ^a   Stadler, Christian H ^b   Poljakovic, Zdravka ^c   Fleet, David ^d   Willeit, Johann ^e   Brainin, Michael ^f   Gruber, Franz ^g   Demarin, Vida ^h   Antoncic, Igor ⁱ   Lusic, Ivo ^j   Bar, Michal ^k   Vaclavik, Daniel ^l   Polivka, Jiri ^m   Rektor, Ivan ⁿ   Turcani, Peter ^o   Svigelj, Viktor ^p  

^a St John of God Hospital   (Austria)

^b LKH Klagenfurt ^*  (Austria)

^c UNIVERSITY OF ZAGREB   (Croatia)

^d Laburnum House East Grimstead Data Magik Ltd   (United Kingdom)

^e UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^f Landesklinikum Tulln   (Austria)

^g KEPLER UNIVERSITY HOSPITAL   (Austria)

^h University Hospital Sorrores Misericordiae   (Croatia)

ⁱ KBC RIJEKA   (Croatia)

^j UNIVERSITY HOSPITAL SPLIT   (Croatia)

^k Clinic of Neurology   (Czech Republic)

^l Vitkovice vyzkum a vyvoj technicke aplikace as   (Czech Republic)

^m CHARLES UNIVERSITY   (Czech Republic)

ⁿ ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^o Bratislava   (Slovakia)

^p Department of Gynecological Pathology and Cytology   (Slovenia)

more..

Author keywords

Cerebrolysin; Neuroprotection; Neurotrophic activity; Recovery; Thrombolysis

Indexed keywords

ALTEPLASE; CEREBROLYSIN;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; TREATMENT OUTCOME;

ADULT; AGED; AMINO ACIDS; BRAIN ISCHEMIA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; PROSPECTIVE STUDIES; STROKE; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872770804     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2012.00901.x     Document Type: Article

References (32)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue Plasminogen Activator for Acute Ischemic Stroke. N Engl J Med 1995; 333:1581-1588.
2. Hacke W, Kaste M, Bluhmki E etal. Thrombolysis with alteplase 3 to 4·5h after acute ischemic stroke. N Engl J Med 2008; 25:1317-1329.
3. Lees KR. Advances in neuroprotection trials. Eur Neurol 2001; 45:6-10.
4. Diener HC, Lees KR, Lyden P etal. NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials. Stroke 2008; 39:1751-1758.
5. Ginsberg MD. Neuroprotection for ischemic stroke: past, present and future. Neuropharmacology 2008; 55:363-389.
6. Kalluri HS, Dempsey RJ. Growth factors, stem cells, and stroke. Neurosurg Focus 2008; 24:E14.
7. Leker RR, Lasri V, Chernoguz D. Growth factors improve neurogenesis and outcome after focal cerebral ischemia. J Neural Transm 2009; 116:1397-1402.
8. Zhu W, Fan Y, Frenzel T etal. Insulin growth factor-1 gene transfer enhances neurovascular remodeling and improves long-term stroke outcome in mice. Stroke 2008; 39:1254-1261.
9. Grotta J. Neuroprotection is unlikely to be effective in humans using current trial designs. Stroke 2002; 33:306-307.
10. Stroke Therapy Academic Industry Roundtable II (STAIR-II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke 2001; 32:1598-1606.
11. Shuaib A. Neuroprotection - STAIR-way to the future? Cerebrovasc Dis 2006; 22:10-17.
12. Davis S. Optimising clinical trial design for proof of neuroprotection in acute ischaemic stroke: the SAINT clinical trial programme. CerebrovascDis 2006; 22:18-24.
13. Ren J, Sietsma D, Qiu S, Moessler H, Finklestein SP. Cerebrolysin enhances functional recovery following focal cerebral infarction in rats. Restor Neurol Neurosci 2007; 25:25-31.
14. Hanson LR, Liu XF, Ross TM etal. Cerebrolysin reduces infarct volume in a rat model of focal cerebral ischemic damage. Am J Neuroprotec Neuroregen 2009; 1:62-68.
15. Gutmann B, Hutter-Paier B, Skofitsch G, Windisch M, Gmeinbauer R. In vitro models of brain ischemia the peptidergic drug cerebrolysin protects cultured chick cortical neurons from cell death. Neurotox Res 2002; 4:59-65.
16. Schauer E, Wronski R, Patockova J etal. Neuroprotection of Cerebrolysin in tissue culture models of brain ischemia: post lesion application indicates a wide therapeutic window. J. Neural Transm 2006; 113:855-868.
17. Sugita Y, Kondo T, Kanazawa A, Itou T, Mizuno Y. Protective effect of FPF (Cerebrolysin) on delayed neuronal death in the gerbil - detection of hydroxyl radicals with salicylic acid. Brain and Nerve 1993; 45:325-331.
18. Zhang C, Chopp M, Cui Y etal. Cerebrolysin enhances neurogenesis in the ischemic brain and improves functional outcome after stroke. J Neurosci Res 2010; 88:3275-3281.
19. Chukanova EI. The effect of cerebrolysin on the clinical symptoms and the course of ischemic encephalopathy. Zh Nevrol Psikhiatr Im S S Korsakova 2005; 105:42-45.
20. Gusev EI, Burd GS, Gekht AB etal. Clinical and neurophysiological study of Cerebrolysin effect on brain state at acute and early recovery stages of hemisphere ischemic insult: cliniconeurophysiological study. ZH Neuropatol Psikhiatr Korsakow 1994; 94:9-13.
21. Koppi S, Barolin GS. Use of cerebrolysin in the treatment of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 1998; 98:30-33.
22. Ladurner G, Kalvach P, Moessler H. Neuroprotective treatment with Cerebrolysin in patients with acute stroke a randomised controlled trial. J Neural Transm 2005; 112:415-428.
23. Skvortsova VI, Stakhovskaia LV, Gubskii LV, Shamalov NA, Tikhonova IV, Smychkov AS. A randomized, double-blind, placebo-controlled study of Cerebrolysin safety and efficacy in the treatment of acute ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2004; (Suppl. 11):51-55.
24. Hill MD, Buchan AM. Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study. Can Med Assn J 2005; 172:1307-1312.
25. Baker WF. Thrombolytic therapy: current clinical practice. Hematol Oncol Clin N Am 2005; 19:147-181.
26. Chavez JC, Hurko O, Barone FC, Feuerstein GZ. Pharmacologic interventions for stroke: looking beyond the thrombolysis time window into the penumbra with biomarkers, not a stopwatch. Stroke 2009; 40:e558-563.
27. Deb P, Sharma S, Hassan KM. Pathophysiologic mechanisms of acute ischemic stroke: an overview with emphasis on therapeutic significance beyond thrombolysis. Pathophysiology 2010; 17:197-218.
28. Davis S, Donnan G. The ECASS III results and the tPA paradox. Int J Stroke 2009; 4:17-18.
29. Schwab M, Antonow-Schlorke I, Zwiener U, Bauer R. Brain-derived peptides reduce the size of cerebral infarction and loss of MAP2 immunoreactivity after focal ischemia in rats. J Neural Transm Suppl 1998; 53:299-311.
30. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995; 333:1581-1587.
31. Wahlgren N, Ahmed N, Davalos A etal. Thrombolysis with alteplase 3-4·5h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet 2008; 372:1303-1309.
32. Lees KR, Davalos A, Davis SM etal. Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. Stroke 2006; 37:2970-2978.